Skip to main content
SpringerLink
Log in

Disorders of Peripheral Nerves

  • Chapter
Prognosis of Neurological Diseases

  • 1425 Accesses

Abstract

Peripheral neuropathies are heritable or acquired.

  1. A.

    Heritable defects, among others:

    1. 1.

      Chronic hereditary motor-sensory neuropathies (HMSN alias Charcot-Marie-Tooth), hereditary motor-sensory neuropathies (HMSN), hereditary sensory and autonomic neuropathies (HSAN), hereditary neuralgic amyotrophy (HNA)

    2. 2.

      Relapsing/progressive motor-sensory polyneuropathies (i.e., Refsum disease)

    3. 3.

      Chronic, progressive, motor-sensory polyneuropathies with early small-fiber involvement (e.g., familial amyloid polyneuropathies)

    4. 4.

      Painful neuropathies (e.g., Fabry disease)

    5. 5.

      Acute generalized polyneuropathies (porphyrias)

    6. 6.

      Chronic sensory neuronopathies associated with ataxias

    7. 7.

      Chronic sensory (and motor) neuropathies due to mitochondrial disorders

    8. 8.

      Recurrent focal neuropathies/plexopathies [hereditary neuropathy with liability to pressure palsies (HNPP); hereditary neuralgic amyotrophy (HNA)]

    Outcome and disability – Most patients with CMT1A and CMT1X do not require ambulation aids. FAP, if untreated, has a relentless fatal course. HNPP has normal life expectancy and good quality of life in most patients.

    Acute intermittent porphyria: the long-term prognosis depends on successful prevention of attacks.

  2. B.

    Acquired forms, among others:

    Immunomediated neuropathies: acute inflammatory polyradiculoneuropathies (AIDP), chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), multifocal motor neuropathy (MMN)

    Outcome and disability – AIDP: 5 % of patients die. CIDP: age <45 years predicts a better outcome; axonal loss forecasts poorer prognosis. MMN: very uncommon spontaneous remissions. Anti-MAG: 25 % of patients disabled after 10 years. POEMS: chronic and invalidating; 50 % of patients are bedridden; mean survival ranges 12–165 months.

Non-systemic vasculitic neuropathy (NSVN): usually not fatal; NSVN may become systemic in 10 % of patients.

Diabetic Neuropathies

Distal symmetric polyneuropathy (DSP): slowly progressive; can stabilize or improve with tight control of diabetes. Autonomic neuropathy: increases the risk of adverse cardiovascular events. Radiculoplexopathy: monophasic, self-limiting evolution.

Carpal tunnel syndrome (CTS): pain tends to decrease with time. One-third of patients have spontaneous improvement.

Bell palsy: healing occurs within 6 months in 80 % of patients.

Peripheral nerve injury (PNI) – Neurapraxic lesions usually recover within a few months. Surgery: the sooner the nerve is repaired the better the functional recovery will be.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Klein CJ, Duan X, Shy ME. Inherited neuropathies: clinical overview and update. Muscle Nerve. 2013;48:604–22.

    Article  PubMed Central  PubMed  Google Scholar 

  2. Pareyson D, Piscosquito G, Moroni I, et al. Peripheral neuropathy in mitochondrial disorders. Lancet Neurol. 2013;12:1011–24.

    Article  CAS  PubMed  Google Scholar 

  3. Rossor AM, Polke JM, Reilly MM. Clinical implications of genetic advances in Charcot-Marie-Tooth disease. Nat Rev Neurol. 2013;9:562–71.

    Article  CAS  PubMed  Google Scholar 

  4. Koike H, Hirayama M, Yamamoto M, et al. Age related associated axonal features in HNPP with 17p11.2 deletion in Japan. J Neurol Neurosurg Psychiatry. 2005;76:1109–14.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  5. Ando Y, Coelho T, Berk JL, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013;8:31.

    Article  PubMed Central  PubMed  Google Scholar 

  6. Cappellari M, Cavallaro T, Ferrarini M, et al. Variable presentation of TTR-related familial amyloid polyneuropathy in seventeen patients. J Peripher Nerv Syst. 2011;16:119–29.

    Article  PubMed  Google Scholar 

  7. Benson MD. Liver transplantation and transthyretin amyloidosis. Muscle Nerve. 2013;47:157–62.

    Article  CAS  PubMed  Google Scholar 

  8. Obici L, Merlini G. An overview of drugs currently under investigation for the treatment of transthyretin-related hereditary amyloidosis. Expert Opin Investig Drugs. 2014;23:1239–51.

    Article  CAS  PubMed  Google Scholar 

  9. Wakerley BR, Uncini A, Yuki N for the GBS Classification Group. Guillain-Barré and Miller-Fisher syndromes – new diagnostic classification. Nat Rev Neurol. 2014;10:537–44.

    Google Scholar 

  10. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol. 1990;27(Suppl):S21–4.

    Article  PubMed  Google Scholar 

  11. Fokke C, van den Berg B, Drenthen J, et al. Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria. Brain. 2014;137:33–43.

    Article  PubMed  Google Scholar 

  12. Durand MC, Porcher R, Orlikowski D, et al. Clinical and electrophysiological predictors of respiratory failure in Guilla-Barré syndrome: a prospective study. Lancet Neurol. 2006;5:1021–8.

    Article  PubMed  Google Scholar 

  13. Walgaard C, Lingsma HF, Ruts L, et al. Prediction of respiratory insufficiency in Guillain-Barré syndrome. Ann Neurol. 2010;67:781–7.

    PubMed  Google Scholar 

  14. Van Koningsveld R, Stevenberg EW, Hughes RA, et al. A clinical prognostic scoring system for Guillain-Barré syndrome. Lancet Neurol. 2007;6:589–94.

    Article  PubMed  Google Scholar 

  15. Rajabally YA, Nicolas G, Piéret F, et al. Validity of diagnostic criteria for chronic inflammatory demyelinating polyneuropathy: a multicentre European study. J Neurol Neurosurg Psychiatry. 2009;80:1364–8.

    Article  CAS  PubMed  Google Scholar 

  16. Van den Bergh PYK, Hadden RDM, Bouche P, et al; European Federation of Neurological Societies; Peripheral Societies. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Society – First revision. Eur J Neurol. 2010;17:356–3.

    Google Scholar 

  17. Nobile-Orazio E, Cocito D, Jann S, et al. Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial. Lancet Neurol. 2012;11:493–502.

    Article  CAS  PubMed  Google Scholar 

  18. van Schaik IN, Eftimov F, van Doorn PA, et al. Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial. Lancet Neurol. 2010;9:245–53.

    Article  PubMed  Google Scholar 

  19. Viala K, Maisonobe T, Stoikovic T, et al. A current view of the diagnosis, clinical variants, response to treatment and prognosis of chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst. 2010;15:50–6.

    Article  CAS  PubMed  Google Scholar 

  20. Bouchard C, Lacroix C, Planté V, et al. Clinicopathological findings and prognosis of chronic inflammatory demyelinating polyneurpathy. Neurology. 1999;52:498–503.

    Article  CAS  PubMed  Google Scholar 

  21. Živković SA, Peltier AC, Iacob T, Lacomis D. Chronic inflammatory demyelinating polyneuropathy and ventilatory failure: report of seven new cases and review of the literature. Acta Neurol Scand. 2011;124:59–63.

    Article  PubMed  Google Scholar 

  22. Rabin M, Mutlu G, Syojkovic T, et al. Chronic inflammatory demyelinating polyradiculoneuropathy: search for factors associated with treatment dependence or successful withdrawal. J Neurol Neurosurg Psychiatry. 2014;85:899–904.

    Google Scholar 

  23. Gorson KC, van Schaik IN, Merkies IS, et al. Chronic inflammatory demyelinating polyneuropathy disease activity status: recommendations for clinical research standards and use in clinical practice. J Peripher Nerv Syst. 2010;15:326–33.

    Article  PubMed  Google Scholar 

  24. Huijbers MG, Querol LA, Niks EH, et al. The expanding field of IgG4-mediated neurological autoimmune disorders. Eur J Neurol. 2015;22:1151–61.

    Google Scholar 

  25. McMillan HJ, Kang PB, Jones HR, Darras BT. Childhood chronic inflammatory demyelinating polyradiculoneuropathy: combined analysis of a large cohort and eleven published series. Neuromuscul Disord. 2013;23:103–11.

    Article  PubMed  Google Scholar 

  26. Uncini A, Susuki K, Yuki N. Nodo-paranodopathy: beyond the demyelinating and axonal classification in anti-ganglioside antibody-mediated neuropathies. Clin Neurophysiol. 2013;124:1928–34.

    Article  PubMed  Google Scholar 

  27. Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society – first revision, Joint Task Force of the EFNS and the PNS. J Peripher Nerv Syst. 2010;15:295–301.

    Article  Google Scholar 

  28. Pestronk A, Chuquillin M, Choksi R. Motor neuropathies and serum IgM binding to NS6S heparin disaccharide or GM1 ganglioside. J Neurol Neurosurg Psychiatry. 2010;81:726–60.

    Article  PubMed  Google Scholar 

  29. Terenghi F, Cappellari A, Bersano A, et al. How long is IVIg effective in multifocal motor neuropathy? Neurology. 2004;62:666–8.

    Article  CAS  PubMed  Google Scholar 

  30. Vucic S, Black KR, Chong PS, Cros P. Multifocal motor neuropathy: decrease in conduction blocks and reinnervation with long-term IVIg. Neurology. 2004;63:1264–9.

    Article  PubMed  Google Scholar 

  31. Cats EA, van der Pol WL, Piepers S, et al. Correlates of outcome and response to IVIg in 88 patients with multifocal neuropathy. Neurology. 2010;75:818–25.

    Article  CAS  PubMed  Google Scholar 

  32. Nobile Orazio E. Neuropathy and monoclonal gammopathy. Handb Clin Neurol. 2013;115:443–59.

    Article  PubMed  Google Scholar 

  33. Driedger H, Pruzanski W. Plasma cell neoplasia with peripheral polyneuropathy: a study of five cases and a review of the literature. Medicine. 1980;59:301–10.

    Article  CAS  PubMed  Google Scholar 

  34. Dispenzieri A, Kyle RA, Lacy MQ, et al. Definitions and long-term outcome. Blood. 2003;101:2496–506.

    Article  CAS  PubMed  Google Scholar 

  35. Monaco S, Bonetti B, Ferrari S, et al. Complement-mediated demyelination in patients with IgM ömonoclonal gammopathy and polyneuropathy. N Engl J Med. 1990;322:649–52.

    Article  CAS  PubMed  Google Scholar 

  36. Léger JM, Viala K, Nicolas G, et al; RIMAG study group. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy. Neurology. 2013;80:2217–25.

    Google Scholar 

  37. Gwathmey KG, Burns TM, Collins MP, Dyck PJB. Vasculitic neuropathies. Lancet Neurol. 2014;13:67–82.

    Article  PubMed  Google Scholar 

  38. Collins MP, Periquet MI. Isolated vasculitis of the peripheral nervous system. Clin Exp Rheumatol. 2008;26:S118–30.

    CAS  PubMed  Google Scholar 

  39. Collins MP, Dyck PJB, Gronseth GS, et al. Peripheral Nerve Society Guideline on the classification, diagnosis, investigation, and immunosuppressive therapy of non-systemic vasculitic neuropathy: executive summary. J Peripher Nerv Syst. 2010;15:176–84.

    Article  PubMed  Google Scholar 

  40. Callaghan BC, Cheng HT, Stables CL, et al. Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurol. 2012;11:521–34.

    Article  PubMed Central  PubMed  Google Scholar 

  41. Boulton AJM, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, Malik RA, Maser RE, Sosenko JM, Ziegler D. Diabetic neuropathies. Diabetes Care. 2005;28:956–62.

    Article  PubMed  Google Scholar 

  42. Lauria G. Small fibre neuropathies. Curr Opin Neurol. 2005;18:591–7.

    Article  PubMed  Google Scholar 

  43. Lozeron P, Nahum L, Lacroix C, et al. Symptomatic diabetic and non-diabetic neuropathies in a series of 100 diabetics patients. J Neurol. 2002;249:569–75.

    Article  PubMed  Google Scholar 

  44. Callaghan BC, Kerber KA, Lisabeth LL, et al. Role of neurologists and diagnostic tests on the management of distal symmetric polyneuropathy. JAMA Neurol. 2014;71:1143–9.

    Google Scholar 

  45. Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy (technical review). Diabetes Care. 2003;26:1553–79.

    Article  PubMed  Google Scholar 

  46. Coppack SW, Watkins PJ. The natural history of diabetic femoral neuropathy. Q J Med. 1991;79:307–13.

    CAS  PubMed  Google Scholar 

  47. Chan YC, Lo YL, Chan ES. Immunotherapy for diabetic amyotrophy. Cochrane Database Syst Rev. 2012;6:CD006521. doi: 10.1002/14651858.CD006521.

  48. Hui AC, Wong S, Leung CH, et al. A randomized controlled trial of surgery vs steroid injection for carpal tunnel syndrome. Neurology. 2005;64:2074–8.

    Article  CAS  PubMed  Google Scholar 

  49. Padua L, Padua R, Aprile I, et al; Italian CTS Study Group. Carpal tunnel syndrome. Multiperspective follow-up of untreated carpal tunnel syndrome: a multicenter study. Neurology. 2001;56(11):1459–66.

    Google Scholar 

  50. Gilden DH. Clinical practice. Bell’s Palsy. N Engl J Med. 2004;351:1323–31.

    Article  CAS  PubMed  Google Scholar 

  51. Sullivan FM, Swan IR, Donnan PT, et al. Early treatment with prednisolone or acyclovir in Bell’s palsy. N Engl J Med. 2007;357(16):1598–607.

    Article  CAS  PubMed  Google Scholar 

  52. Kouyoumdjian JA. Peripheral nerve injuries: a retrospective survey of 456 cases. Muscle Nerve. 2006;34:785–8.

    Article  PubMed  Google Scholar 

  53. Seddon HJ. Three types of nerve injury. Brain. 1943;66:237–88.

    Article  Google Scholar 

  54. Sunderland S. Nerves and nerve injuries. 2nd ed. New York: Churchill Livingston; 1978. p. 133–8.

    Google Scholar 

  55. Padua L, Di Pasquale A, Liotta G, et al. Ultrasound as a useful tool in the diagnosis and management of traumatic nerve lesions. Clin Neurophysiol. 2013;124(6):1237–43.

    Article  CAS  PubMed  Google Scholar 

  56. Gasparotti R, Lodoli G, Meoded A, Carletti F, Garozzo D, Ferraresi S. Feasibility of diffusion tensor tractography of brachial plexus injuries at 1.5 T. Invest Radiol. 2013;48(2):104–12.

    Article  PubMed  Google Scholar 

  57. Magrinelli F, Zanette G, Tamburin S. Neuropathic pain: diagnosis and treatment. Pract Neurol. 2013;13(5):292–307.

    Article  PubMed  Google Scholar 

  58. Birch R. Surgical disorders of the peripheral nerves. 2nd ed. London/New York: Springer Science and Business Media; 2011. p. 77–114.

    Book  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurological and Movement Sciences, University of Verona, Ospedale Policlinico G.B. Rossi, P.le L.A. Scuro 10, Verona, 37134, Italy

    Gian Maria Fabrizi

  2. Neurology Section, Pederzoli Hospital, Peschiera del Garda, Verona, Italy

    Gian Maria Fabrizi & Giampietro Zanette

Authors
  1. Gian Maria Fabrizi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Giampietro Zanette
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gian Maria Fabrizi .

Editor information

Editors and Affiliations

  1. Fondazione “Giancarlo Quarta”, Milano, Milan, Italy

    Angelo Sghirlanzoni

  2. Istituto Neurologico C. Besta, Milan, Italy

    Giuseppe Lauria

  3. Istituto Neurologico C. Besta, Milan, Italy

    Luisa Chiapparini

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer-Verlag Italia

About this chapter

Cite this chapter

Fabrizi, G.M., Zanette, G. (2015). Disorders of Peripheral Nerves. In: Sghirlanzoni, A., Lauria, G., Chiapparini, L. (eds) Prognosis of Neurological Diseases. Springer, Milano. https://doi.org/10.1007/978-88-470-5755-5_35

Download citation

  • DOI: https://doi.org/10.1007/978-88-470-5755-5_35

  • Publisher Name: Springer, Milano

  • Print ISBN: 978-88-470-5754-8

  • Online ISBN: 978-88-470-5755-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation